Reading Time: < 1 minuteIntroduction Testosterone replacement therapy (TRT), particularly transdermal formulations like Testim® 1% testosterone gel, has become a cornerstone in managing hypogonadism among American males, with over 2.3 million prescriptions annually according to the CDC's National Ambulatory Medical Care Survey (NAMCS) data from 2022. Hypogonadism affects approximately 4-5% of U.S. men aged 40-79, correlating with symptoms beyond sexual dysfunction, including immune dysregulation. Emerging immunological research suggests testosterone modulates Th1/Th2 cytokine balance, potentially influencing allergic diseases prevalent in this demographic. Asthma impacts 7.7% of American adults, with males showing higher hospitalization rates post-40 (CDC, 2023), while allergic rhinitis affects 20-30% of men. This … Continue reading
-
Injectable Sermorelin

-
Search -
Archives
- March 2026
- May 2025
- April 2025
- March 2025
- February 2025
- April 2024
- March 2024
- December 2023
- November 2023
- October 2023
- September 2023
- August 2023
- July 2023
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- February 2019
- January 2019
-
HGH Decline Charts

-
Sermorelin Products

-
Sermorelin Health















